Congrats Joshua Hill, MD!

Through RITN.net, NMDP ASTCT Office of Naval Research (ONR) partner to provide network to assist in managing radiation exposure. Great example of value of HRSA CW Bill Young Transplant Program Department of Defense 🇺🇸 Marrow Donor Program. USCongress

A ​person’s ​race ​and ​health​ insurance ​may​ affect​ which ​treatments ​they​ receive​ for multiple myeloma. Learn more about this recent CIBMTR study: cibmtr.org/Files/Patient-…

For pediatric patients with HCT, overall survival 1-year after ICU admission was only 52% and survivors had excess long-term mortality risk. ow.ly/ebPX50QHhvq #transplantation #healthservicesandoutcomes

True testament to the accomplishments of our transplant and cell therapy ecosystem! ✔️out CIBMTR 2023 Annual Report! Thanks to our network for your contributions and partnership!
NMDP ASTCT

Incredibly profound ASTCT CIBMTR The EBMT session on HCT and cell therapy and the critical need to perform and support research. Sage advice! #Tandem24 Miguel Perales M.D. Anna Sureda michael verneris Mary Horowitz Marcel van den Brink Mette Hazenberg

And so ASTCT CIBMTR 2024 Tandem Meetings begin! Thanks to our SOC chairs, Alan Hanash and Chris Kanakary! Outstanding leadership! #Tandem24

This analysis presents population prevalence estimates of immunosuppression among US adults using nationally representative 2021 data. ja.ma/3I2XAvS

Learn more about reducing access barriers and improving healthcare disparities for all patients in need of cell therapy. Attend the ASTCT NMDP ACCESS Initiative Workshop at this year's ASTCT CIBMTR Tandem Meetings. Together, we will!
astct.org/Advocate/ACCES…

PTCy enables the use of mismatched related (haplo) and unrelated donors (MMUD) for alloHCT. However, its use associates with significant morbidity, including organ toxicity and infection, as per this CIBMTR study. Learn more about optimizing NMDP MMUD HCT outcomes.

In follow up to our first study bit.ly/3OiBxVy, we report the final analysis from the CIBMTR BMT CTN study of early (<4 mo) vs late (4-12 mo) SARS-CoV-2 vaccination after #HCT and #CART in 466 participants. ASTCT Miguel Perales M.D. Jeff Auletta
medrxiv.org/content/10.110…

Let's talk about a shining example of good going a long way: Barbara Buchbinder set a gold standard in pediatric transplant nursing, even while fighting cancer. Her legacy lives on with the NMDP Barbara Buchbinder Nurse Research Program, advancing care in pediatric transplant. 💙

Thank you, The Leukemia & Lymphoma Society, for inviting me to discuss all things transplant and cell therapy, including our field's successes, challenges, and patient barriers and outcome disparities. ASTCT CIBMTR @BeTheMatch
treatingbloodcancers.org/e74/

Researchers checked on nearly 7,000 children who got #BMT in the US or Canada during 2008-2014. About 15% children went back to the hospital ICU within 5 years after transplant. Read about this recent CIBMTR study: cibmtr.org/Files/Patient-…

CONGRESS #ASH23 | Jeff Auletta CIBMTR shares data comparing PTCy prophylaxis between 8/8 and 7/8 URD HCT in adult pts. Multivariable regression analysis showed no significant differences in either GRFS or OS between recipients of 8/8 and 7/8 URD HCT at 1-3 years post-HCT.…

The ACCESS Initiative is a joint collaborative effort between ASTCT & @BeTheMatch to reduce barriers & improve outcome disparities for HCT/CT patients. Read the proceedings from the most recent ASTCT & @BTMPublicPolicy #ACCESS Initiative meeting: ow.ly/6tCj50Qe900

In patients without a matched sibling donor or well-matched unrelated donor, #HCT can still be successful when using an HLA-mismatched unrelated donor in combination with PTCy, abatacept or other novel approaches. Read more: ow.ly/n11y50Qa78H

The National Marrow Donor Program (NMDP) / @BeTheMatch helps people get treated for leukemia, sickle cell disease, and other blood disorders. Read more about this recent study: cibmtr.org/Files/Patient-…